LGND Q4 2018 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+18.1% YoY

Gross Profit

$57M95.0% margin

Operating Income

$33M55.6% margin

Net Income

-$42M-71.3% margin

EPS (Diluted)

$-2.02

QoQ Revenue Growth

+30.5%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$22M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$700M

Stockholders' Equity

$561M

Cash & Equivalents

$718M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$50M	+18.1%
Gross Profit	$57M	$49M	+16.2%
Operating Income	$33M	$28M	+16.9%
Net Income	-$42M	-$7M	-506.0%